+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LRRK2 Inhibitor - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 5262037
This “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Understanding

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson's disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor R&D. The therapies under development are focused on novel approaches for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs Chapters

This segment of the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs

ION859: Ionis Pharmaceuticals ION859 (formerly IONIS-BIIB7Rx), also known as BIIB094, is an investigational antisense medicine targeting Leucine Rich Repeat Kinase 2 (LRRK2) messenger ribonucleic acid (m RNA). It is designed to prevent the production of LRRK2 protein and is currently under Phase II clinical evaluation for Parkinson’s disease (PD). It is hypothesized that reduction of LRRK2 m RNA and, subsequently, reduced synthesis of LRRK2 protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD patients without theLRRK2mutation.

DNL151: Denali Therapeutics DNL151 is a potent, selective and brain-penetrant oral small molecule inhibitor of LRRK2. It is in Phase I clinical development for Parkinson's disease. Denali Therapeutics is developing this drug in collaboration with Biogen. Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor

There are approx. 8+ key companies which are developing the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor. The companies which have their Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Insights

  • Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs?
  • How many Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Ionis Pharmaceuticals
  • Denali Therapeutics
  • Neuron23
  • Voronoi
  • E-Scape Bio

Key Products

  • ION859
  • DNL151
  • Small molecule therapeutics
  • VRN-01
  • ESB-5070


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Analytical Perspective
In-depth Commercial Assessment
  • Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  • Comparative Analysis
ION859: Ionis Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  • Comparative Analysis
DNL151: Denali Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
Leucine-rich repeat kinase 2 inhibitor: Cerevel therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key CompaniesLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key ProductsLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Unmet NeedsLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Market Drivers and BarriersLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor- Future Perspectives and ConclusionLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Analyst ViewsLeucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Key CompaniesAppendix
List of Tables
Table 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ionis Pharmaceuticals
  • Denali Therapeutics
  • Neuron23
  • Voronoi
  • E-Scape Bio